Abstract No. 512 Intraarterial computed tomography–enhancement mapping for response assessment of hepatocellular carcinoma to transarterial chemoembolization: a preliminary analysis

2018 ◽  
Vol 29 (4) ◽  
pp. S215-S216
Author(s):  
B. Odisio ◽  
E. Lin ◽  
G. Chintalapani ◽  
A. Mahvash ◽  
E. Klotz
Keyword(s):  
Computed Tomography ◽  
Hepatocellular Carcinoma ◽  
Transarterial Chemoembolization ◽  
Preliminary Analysis ◽  
Response Assessment

Contrast-Enhanced Ultrasound and Computed Tomography Assessment of Hepatocellular Carcinoma after Transcatheter Arterial Chemo-Embolization: A Systematic Review

2016 ◽  
Vol 25 (4) ◽  
pp. 499-507 ◽  
Author(s):  
Cheng-Jeng Tai ◽  
Ming-Te Huang ◽  
Chih-Hsiung Wu ◽  
Chen-Jei Tai ◽  
Yeu-Ching Shi ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Predictive Value ◽  
Transarterial Chemoembolization ◽  
Therapeutic Response ◽  
Response Assessment ◽  
Contrast Enhanced Ultrasound ◽  
Contrast Enhanced ◽  
The Mean

Background & Aims: Contrast-enhanced ultrasound (CEUS) and contrast-enhanced computed tomography (CECT) are used to assess the response of hepatocellular carcinoma after transarterial chemoembolization. Our aim was to perform a systematic review to compare CEUS and CECT for therapeutic response assessment to transarterial chemoembolization in the treatment of hepatocellular carcinoma. Method: PubMed, Embase, and the Cochrane Library databases were searched from inception until January 1, 2016. Participants: patients with hepatocellular carcinoma. Intervention: transarterial chemoembolization and CECT vs CEUS. Results. Sixteen studies were included in the systematic review. The total number of patients was 858 and the mean patient age ranged from 42 to 73 years. The mean tumor size ranged from 1.0 cm to 4.3 cm. The sensitivity and specificity of CEUS ranged from 46% to 100% and 65% to 100%, respectively, and that of CECT ranged from 34% to 87% and 92% to 100%, respectively. The accuracy of CEUS ranged from 72.6% to 100% and that of CECT from 61% to 94%. Marked heterogeneity was present among the studies. Conclusion: CEUS is comparable with CECT for the therapeutic response assessment after transarterial chemoembolization. Abbreviations: CECT: Contrast-enhanced CT; CEUS: Contrast-enhanced Ultrasound; CT: Computed Tomography; HCC: Hepatocellular Carcinoma; MDCT: Multidetector row CT; MRI: Magnetic Resonance Imaging; mRECIST: modified Response Evaluation Criteria in Solid Tumors; NPV: Negative Predictive Value; PPV: Positive Predictive Value; QUADAS-2: Quality Assessment of Diagnostic Accuracy Studies; RFA: Radiofrequency Ablation; TACE: Transcatheter Arterial Chemoembolization.

Computed Tomography Perfusion Following Transarterial Chemoembolization of Hepatocellular Carcinoma

2017 ◽  
Vol 41 (5) ◽  
pp. 708-712 ◽  
Author(s):  
Thomas Wimmer ◽  
Juergen Steiner ◽  
Emina Talakic ◽  
Rudolf Stauber ◽  
Franz Quehenberger ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Hepatocellular Carcinoma ◽  
Transarterial Chemoembolization ◽  
Computed Tomography Perfusion

scholarly journals A Pretreatment CT Model Predicts Survival Following Chemolipiodolization in Patients With Hepatocellular Carcinoma

2019 ◽  
Vol 18 ◽  
pp. 153303381984448
Author(s):  
Yijun Zhang ◽  
Shuping Qu ◽  
Wanwan Yi ◽  
Jian Zhai ◽  
Xiaobing Zhang ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Microvessel Density ◽  
Transarterial Chemoembolization ◽  
Prognostic Model ◽  
Arterial Phase ◽  
Type I ◽  
Complete Necrosis ◽  
Peak Enhancement

Purpose: To establish a computed tomography–based prognostic model for patients with hepatocellular carcinoma treated with transarterial chemoembolization. Materials and Methods: Using prospectively collected data from 195 consecutive patients with hepatocellular carcinoma who underwent chemolipiodolization at the Eastern Hepatobiliary Surgery Hospital between 2013 and 2016, we established a prognostic model based on hepatocellular carcinoma enhancement patterns on computed tomography scans to predict the outcome of transarterial chemoembolization. Furthermore, a histopathology analysis was performed on 108 different patients undergoing resection between 2014 and 2016 to identify whether there was a correlation between enhancement pattern and microvessel density. Results: The prognostic model classified hepatocellular carcinoma into 3 types: type I, which reached peak enhancement during the arterial phase and had a high mean microvessel density (101.5 vessels/0.74 mm2); type II, which reached peak enhancement during the portal venous or delayed phase and had an intermediate microvessel density (53.6 vessels/0.74 mm2); and type III, in which the tumor was insignificantly enhanced and had a low microvessel density (21.1 vessels/0.74 mm2). For type I, II, and III hepatocellular carcinoma, the post-transarterial chemoembolization 1-year tumor complete necrosis rates were 13.7%, 36.5%, and 0%, respectively ( P < .001), and the 3-year overall survival rates were 14.1%, 38.6%, and 0%, respectively ( P < .001). Conclusion: Our results indicate that hepatocellular carcinoma type is an independent predictor of complete necrosis and overall survival

A pretreatment CT model predicts survival following chemolipiodolization in patients with hepatocellular carcinoma.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e14509-e14509
Author(s):  
Dong Wu ◽  
Hengwei Fan ◽  
Shuping Qu
Keyword(s):  
Computed Tomography ◽  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Microvessel Density ◽  
Transarterial Chemoembolization ◽  
Prognostic Model ◽  
Arterial Phase ◽  
Type I ◽  
Complete Necrosis ◽  
Peak Enhancement

e14509 Background: This study aimed to establish a computed tomography-based prognostic model for patients with hepatocellular carcinoma treated with transarterial chemoembolization. Methods: Using prospectively collected data from 195 consecutive patients with hepatocellular carcinoma who underwent chemolipiodolization at the Eastern Hepatobiliary Surgery Hospital between 2013 and 2016, we established a prognostic model based on hepatocellular carcinoma enhancement patterns on computed tomography scans to predict the outcome of transarterial chemoembolization. Furthermore, a histopathology analysis was performed on 108 different patients undergoing resection between 2014 and 2016 to identify whether there was a correlation between enhancement pattern and microvessel density. Results: The prognostic model classified hepatocellular carcinoma into 3 types: Type I, which reached peak enhancement during the arterial phase and had a high mean microvessel density (101.5 vessels/0.74 mm2); Type II, which reached peak enhancement during the portal venous or delayed phase and had an intermediate microvessel density (53.6 vessels/0.74 mm2); and Type III, in which the tumor was insignificantly enhanced and had a low microvessel density (21.1 vessels/0.74 mm2). For type I, II, and III hepatocellular carcinoma, the post-transarterial chemoembolization 1-year tumor complete necrosis rates were 13.7%, 36.5%, and 0%, respectively (p < 0.001) and the 3-year overall survival rates were 14.1%, 38.6%, and 0%, respectively (p < 0 .001). Conclusions: Our results indicate that hepatocellular carcinoma type is an independent predictor of complete necrosis and overall survival.

Sign in / Sign up

Export Citation Format

Share Document